Global Antibody Drug Conjugates (ADCs) Market Size & Trends Report Segmented by Product (Kadcyla, Padcev, Enhertu, Adcetris, Trodelvy), Application (Breast Cancer, Blood Cancer), Target (HER2, CD22, CD30), Technology & Regional Forecasts to 2030
The antibody drug conjugates (ADCs) market is projected to grow at a CAGR of ~9% over the forecast period. Major factors driving growth include the growing prevalence of cancer, increasing demand for targeted cancer therapies, advancement in ADC technology, growing investment in R&D for introducing new antibody-drug conjugates, and increasing approvals by regulatory bodies such as the FDA and EMA for ADCs. However, the market encounters certain challenges, including the high cost of development, stringent regulatory requirements that make the approval process lengthy and expensive, and increasing competition from emerging therapies. To learn more about the research report, download a sample report.
Report Overview
Antibody-drug conjugates or ADCs are a novel class of highly potent biopharmaceuticals consisting of a monoclonal antibody chemically linked to a biologically active drug or cytotoxic compound. These targeted therapies harness the precise targeting capabilities of antibodies, enabling accurate differentiation between healthy and cancerous tissues, while delivering the cell-killing effects of cytotoxic agents. An ideal ADC has:
- A highly selective monoclonal antibody (mAb) for a tumor-associated antigen that has restricted or no expression on normal (healthy) cells
- A potent cytotoxic agent (generally a small molecule drug with high systemic toxicity) designed to induce target cell death after being internalized in the tumor cell and released
- A linker that is stable in circulation, but releases the cytotoxic agent in target cells
To learn more about this report, download the PDF brochure
Growing prevalence of cancer is expected to drive market growth
Cancer remains one of the leading causes of death globally. According to GLOBOCAN 2024, in 2022, nearly 20 million new cancer cases were reported, alongside 9.7 million cancer-related deaths worldwide. Therapeutic approaches for treating cancer or tumors include chemotherapy, immunotherapy, radiation therapy, stem cell therapy, laser treatment, hyperthermia, surgery, and photodynamic therapy, among others. Among these, chemotherapy remains the primary treatment method.
However, antibody-drug conjugates (ADCs) are rapidly gaining attention due to their unique capability to combine targeted therapy with potent cytotoxic agents while leaving healthy cells unharmed. This innovative approach provides a promising solution for treating various types of cancers, including those resistant to conventional therapies. To date, 14 ADCs have received market approval for the treatment of different cancers, with over 200 currently undergoing clinical development. Further, ADCs are revolutionizing cancer treatment by offering a highly specific mechanism of action, delivering targeted and effective therapy, and bringing new hope to cancer patients worldwide.
Technological advancements in antibody-drug conjugate (ADC) technology to propel market growth
Continuous advancements in the design and development of antibody-drug conjugates (ADCs) have significantly improved their efficacy and safety, making them increasingly attractive as treatment options. These innovations span several critical areas, including antibody engineering, linker technology, cytotoxic payloads, and manufacturing processes.
One breakthrough is the adoption of site-specific conjugation techniques, which provide precise control over the drug-to-antibody ratio, enhancing the consistency and therapeutic performance of ADCs. Another key innovation is the development of novel linkers that respond to specific conditions, such as the low pH in the tumor microenvironment, enabling targeted drug release and reducing off-target toxicity. Additionally, advances in antibody engineering and selection have led to the creation of antibodies with enhanced binding specificity, affinity, and pharmacokinetics, further boosting the potency and effectiveness of ADCs. Improvements in manufacturing technologies, such as the integration of single-use systems, have addressed some of the production challenges, increasing efficiency and scalability. As research in ADCs continues to progress, even more sophisticated and effective technologies are expected to emerge, broadening the scope of their applications.
To learn more about this report, download the PDF brochure
Competitive Landscape Analysis
The global antibody drug conjugates (ADCs) market is marked by the presence of established and emerging market players such as Takeda Pharmaceutical Company Ltd.; AstraZeneca PLC; F. Hoffmann-La Roche Ltd.; Pfizer, Inc.; AbbVie’s; Gilead Sciences, Inc.; Merck & Co.; ADC Therapeutics SA; Bolt Biotherapeutics; Mersana Therapeutics; and Daiichi Sankyo Company Ltd.; among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and investments.
Report Scope
| Report Metric | Details |
| Base Year Considered | 2024 |
| Historical Data | 2023 - 2024 |
| Forecast Period | 2025 - 2030 |
| Growth Rate | 9% |
| Market Drivers |
|
| Attractive Opportunities |
|
| Segment Scope | Product, Application, Target, and Technology |
| Regional Scope |
|
| Key Companies Mapped | Takeda Pharmaceutical Company Ltd.; AstraZeneca PLC; F. Hoffmann-La Roche Ltd.; Pfizer, Inc.; AbbVie’s; Gilead Sciences, Inc.; Merck & Co.; ADC Therapeutics SA; Bolt Biotherapeutics; Mersana Therapeutics; and Daiichi Sankyo Company Ltd. |
| Report Highlights | Market Size & Forecast, Growth Drivers & Restraints, Trends, Competitive Analysis |
Global Antibody Drug Conjugates (ADCs) Market Segmentation
This report by Medi-Tech Insights provides the size of the global antibody drug conjugates (ADCs) market at the regional- and country-level from 2023 to 2030. The report further segments the market based on product, application, target, and technology.
Market Size & Forecast (2023-2030), By Product, USD Million
- Kadcyla
- Enhertu
- Adcetris
- Padcev
- Trodelvy
- Polivy
- Others
Market Size & Forecast (2023-2030), By Application, USD Million
- Breast Cancer
- Blood Cancer
- Other Cancers
Market Size & Forecast (2023-2030), By Target, USD Million
- HER2
- CD22
- CD30
- Others
Market Size & Forecast (2023-2030), By Technology USD Million
- Linker Type
- Cleavable Linker
- Non-cleavable Linker
- Linker less
- Payload Technology
- MMAE/ Auristatin
- Maytansinoids
- Camptothecin
- Others
Market Size & Forecast (2023-2030), By Region, USD Million
- North America
- US
- Canada
- Europe
- UK
- Germany
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Rest of Asia Pacific
- Latin America
- Middle East & Africa
Key Strategic Questions Addressed
- What is the market size & forecast of the antibody drug conjugates (ADCs) market?
- What are the historical, present, and forecasted market shares and growth rates of various segments and sub-segments of the antibody drug conjugates (ADCs) market?
- What are the key trends defining the market?
- What are the major factors impacting the market?
- What are the opportunities prevailing in the market?
- Which region has the highest share in the global market? Which region is expected to witness the highest growth rate in the next 5 years?
- Who are the major players operating in the market?
- What are the key strategies adopted by players?
- Introduction
- Introduction
- Market Scope
- Market Definition
- Segments Covered
- Regional Segmentation
- Research Timeframe
- Currency Considered
- Study Limitations
- Stakeholders
- List of Abbreviations
- Key Conferences and Events (2025-2026)
- Research Methodology
- Secondary Research
- Primary Research
- Market Estimation
- Bottom-Up Approach
- Top-Down Approach
- Market Forecasting
- Executive Summary
- Antibody Drug Conjugates (ADCs) Market Snapshot (2025-2030)
- Segment Overview
- Regional Snapshot
- Competitive Insights
- Market Overview
- Market Dynamics
- Drivers
- Growing prevalence of cancer
- Advancement in ADC technology
- Increasing demand for targeted cancer therapies
- Growing investment in R&D for introducing new antibody-drug conjugates
- Increasing approvals by regulatory bodies such as the FDA and EMA for ADCs
- Restraints
- High development cost
- Stringent regulatory requirements that make the approval process lengthy and expensive
- Increasing competition from emerging therapies
- Opportunities
- Expansion into non-oncology indications
- Leveraging ADCs in combination with existing immunotherapies
- Rising demand for targeted therapies
- Key Market Trends
- Leveraging AI for target identification, drug design, and optimization of ADC properties
- Growing focus on patient-centric approaches
- Advancement in ADC manufacturing process
- Unmet Market Needs
- Industry Speaks
- Global Antibody Drug Conjugates (ADCs) Market Size & Forecast (2023-2030), By Product USD Million
- Introduction
- Kadcyla
- Enhertu
- Adcetris
- Padcev
- Trodelvy
- Polivy
- Others
- Global Antibody Drug Conjugates (ADCs) Market Size & Forecast (2023-2030), By Application USD Million
- Introduction
- Breast Cancer
- Blood Cancer
- Other Cancers
- Global Antibody Drug Conjugates (ADCs) Market Size & Forecast (2023-2030), By Target USD Million
- Introduction
- HER2
- CD22
- CD30
- Others
- Global Antibody Drug Conjugates (ADCs) Market Size & Forecast (2023-2030), By Technology USD Million
- Introduction
- Linker Type
- Cleavable Linker
- Non-cleavable Linker
-
- Linker less
-
- Payload Technology
- MMAE/ Auristatin
- Maytansinoids
- Camptothecin
- Others
- Payload Technology
- Global Antibody Drug Conjugates (ADCs) Market Size & Forecast (2023-2030), By Region, USD Million
- Introduction
- North America Antibody Drug Conjugates (ADCs) Market Size & Forecast (2023-2030), By Country, USD Million
- US
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Target (USD Million)
- Market Size & Forecast, By Technology (USD Million)
- Canada
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Target (USD Million)
- Market Size & Forecast, By Technology (USD Million)
- US
- Europe Antibody Drug Conjugates (ADCs) Market Size & Forecast (2023-2030), By Country, USD Million
- UK
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Target (USD Million)
- Market Size & Forecast, By Technology (USD Million)
- Germany
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Target (USD Million)
- Market Size & Forecast, By Technology (USD Million)
- Italy
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Target (USD Million)
- Market Size & Forecast, By Technology (USD Million)
- Spain
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Target (USD Million)
- Market Size & Forecast, By Technology (USD Million)
- Rest of Europe
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Target (USD Million)
- Market Size & Forecast, By Technology (USD Million)
- UK
- Asia Pacific (APAC) Antibody Drug Conjugates (ADCs) Market Size & Forecast (2023-2030), By Country, USD Million
- China
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Target (USD Million)
- Market Size & Forecast, By Technology (USD Million)
- Japan
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Target (USD Million)
- Market Size & Forecast, By Technology (USD Million)
- India
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Target (USD Million)
- Market Size & Forecast, By Technology (USD Million)
- Rest of Asia Pacific
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Target (USD Million)
- Market Size & Forecast, By Technology (USD Million)
- China
- Latin America (LATAM) Antibody Drug Conjugates (ADCs) Market Size & Forecast (2023-2030), USD Million
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Target (USD Million)
- Market Size & Forecast, By Technology (USD Million)
- Middle East & Africa (MEA) Antibody Drug Conjugates (ADCs) Market Size & Forecast (2023-2030), USD Million
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By Target (USD Million)
- Market Size & Forecast, By Technology (USD Million)
- Competitive Landscape
- Key Players and their Competitive Positioning
- Key Player Comparison
- Segment-wise Player Mapping
- Market Share Analysis (2024)
- Company Categorization Matrix
- Dominants/Leaders
- New Entrants
- Emerging Players
- Innovative Players
- Key Strategies Assessment, By Player (2022-2024)
- New Product Launches
- Partnerships, Agreements, & Collaborations
- Mergers & Acquisitions
- Key Players and their Competitive Positioning
- Company Profiles*
(Business Overview, Financial Performance**, Products Offered, Recent Developments)
- AbbVie’s
- Takeda Pharmaceutical Company Ltd.
- AstraZeneca PLC
- Hoffmann-La Roche Ltd.
- Pfizer, Inc.
- Mersana Therapeutics
- Gilead Sciences, Inc.
- Merck & Co.
- ADC Therapeutics SA
- Daiichi Sankyo Company Ltd.
- Other Prominent Players
Note: *Indicative list
**For listed companies
The study has been compiled based on extensive primary and secondary research.
Secondary Research (Indicative List)
Primary Research
To validate research findings (market size & forecasts, market segmentation, market dynamics, competitive landscape, key industry trends, etc.), extensive primary interviews were conducted with both supply and demand-side stakeholders.
Supply Side Stakeholders:
- Senior Management Level: CEOs, Presidents, Vice-Presidents, Directors, Chief Technology Officers, Chief Commercial Officers
- Mid-Management Level: Product Managers, Sales Managers, Brand Managers, R&D Managers, Business Development Managers, Consultants
Demand Side Stakeholders:
- Stakeholders from Hospitals & Specialty Clinics, Academic & Research Institutes and Others
Breakdown of Primary Interviews
Market Size Estimation
Both ‘Top-Down & Bottom-Up Approaches’ were used to derive market size estimates and forecasts.
Data Triangulation
Research findings derived through secondary sources & internal analysis were validated with Primary Interviews, the Internal Knowledge Repository, and the Company’s Sales Data.
